Overexpression of apoptosis-related protein, survivin, in fibroblasts from patients with systemic sclerosis
Adult
Male
0303 health sciences
Scleroderma, Systemic
Survivin
Ubiquitin-Protein Ligases
Apoptosis
Fibroblasts
Middle Aged
Baculoviral IAP Repeat-Containing 3 Protein
Inhibitor of Apoptosis Proteins
Up-Regulation
03 medical and health sciences
Case-Control Studies
Humans
Female
RNA, Messenger
Cells, Cultured
DOI:
10.1007/s11845-019-01978-w
Publication Date:
2019-02-13T22:24:30Z
AUTHORS (7)
ABSTRACT
Recent studies suggest that, in addition to activation and hypersecretion of matrix components, fibroblasts from patients with systemic sclerosis (SSc) are resistant to apoptosis. Previous studies have shown that survivin, a member of inhibition of apoptosis (IAP) family, plays an important role in apoptosis resistance. Accordingly, we decided to study the expression of the most important members of IAP family in SSc fibroblasts, which can block apoptosis either by binding and inhibiting caspases or through caspase-independent mechanisms.Skin biopsy samples were obtained from 19 patients with diffuse cutaneous SSc (DcSSc) and 16 healthy controls. Dermal fibroblasts were cultured and the total RNA was isolated from cells followed by cDNA synthesis. Real-time PCR was performed using SYBR Green PCR master mix and specific primers for cIAP1, cIAP2, XIAP, and Survivin mRNA quantification.A significantly increased expression level of Survivin was observed in fibroblasts from SSc patients compared to controls (2.26-fold, P = 0.04). However, mRNA expression of cIAP1, cIAP2, and XIAP did not change significantly between cases and controls.Our results showed that survivin is upregulated in SSc skin fibroblast which may lead to resistance to apoptosis. Further studies should be performed to reveal the role of survivin in apoptosis pathway of SSc fibroblasts.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (45)
CITATIONS (8)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....